表紙
市場調査レポート

幹細胞市場

Stem Cell Markets

発行 TriMark Publications 商品コード 120863
出版日 ページ情報 英文 306 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
幹細胞市場 Stem Cell Markets
出版日: 2013年08月01日 ページ情報: 英文 306 Pages
概要

当レポートでは、幹細胞を研究開発の目的で利用している医療研究領域の市場セグメントに関する解説を行い、現在、幹細胞の準備/利用に一般的に採用されている全ての分析方法のレビュー、疾患の新しい治療法の開発に利用される幹細胞について調査を行っており、概略下記の内容でお届けいたします。

第1章 概要

第2章 幹細胞の生物学

  • 本章の範囲
  • 幹細胞の基本的特性
  • ヒト幹細胞の種類
  • 臍帯幹細胞
  • 成体会細胞
  • iPS細胞

第3章 創薬におけるイネーブリング技術としての幹細胞

  • 現在のHTSにおける不死化細胞および一次細胞
  • HTSおよび創薬における成体幹細胞
  • HTSおよび創薬におけるiPS細胞

第4章 細胞療法市場における治験:概要

  • フェーズ?治験において間もなく達成される予定の15の細胞と幹細胞療法
  • 細胞療法の治験:地域別
  • 細胞療法の治験:上位10カ国
  • 細胞療法の治験:資金提供の種類
  • 細胞療法の治験:細胞種類別
  • 細胞療法の治験:幹細胞種類別
  • 非幹細胞を含めた幹細胞療法の治験
  • MSCそ含めた細胞療法:ソース別
  • 幹細胞を含めた治験:ドナータイプ別
  • 細胞療法の治験:適応症別
  • 細胞・組織療法の治験:開発段階別
  • 欧州における臨床開発

第5章 幹細胞研究の資金提供

  • 本章の範囲
  • 資金提供に対する激しい競争圧力
  • 主要諸国における資金提供

第6章 主要国における幹細胞活動

  • 米国
  • カナダ
  • 英国
  • スウェーデン
  • ブラジル

第7章 市販の細胞療法製品

第8章 再生医療産業:概要

  • 再生医療産業の主要区分
  • 再生医療の3つの主な2次市場
  • 細胞・組織ベースの企業:ロケーション別
  • 細胞・組織ベースの治験:ロケーション別
  • 販売中またはテスト中の細胞・組織療法
  • 治療企業の分析
  • 遺伝子療法の治験

第9章 細胞療法産業:概要

  • 細胞ベースの治療
  • 細胞・組織バンキング
  • 組織工学・幹細胞企業の産業パラメーター
  • 米国における幹細胞の利用
  • 欧州における細胞療法・再生医療企業

第10章 細胞療法産業:市場分析

  • 細胞療法・再生医療の経済的メリット
  • 細胞療法産業・資本形成
  • 細胞療法市場規模・市場額
  • CTIの構造
  • CTIの製薬、バイオテクノロジーおよび医療装置産業への相補性
  • 細胞療法の調査から開発
  • 幹細胞企業の市場資本化
  • 幹細胞の世界市場
  • 臍帯血バンキング
  • 眼科における細胞療法市場
  • 癌における細胞療法
  • 心臓病・血管疾患向けCT・TE製品の世界市場
  • 神経学におけるCT・RM製品市場
  • 整形外科、筋骨格系および脊椎疾患向けCT・TE製品の世界市場
  • 皮膚/外皮向けCT・TE製品の世界市場
  • 歯科における細胞療法
  • 細胞培養市場

第11章 毒性試験

  • 毒性試験
  • 毒性試験における動物利用の歴史
  • 動物試験から逸れる理由
  • 代わりの方法

第12章 細胞療法市場における注目のイベント

  • 細胞療法市場における臨床上のマイルストーン
  • 細胞療法市場における最近の買収・提携
  • 細胞療法市場における注目の資金提供
  • 細胞療法市場において製薬会社の関与は限定的

第13章 幹細胞研究で用いられるマーカー

第14章 企業プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRSTEM13-0801

Abstract

A stem cell is an extraordinary type of cell that has the ability to self-renew for long periods of time and to differentiate into specialized cells under appropriate physiological or experimental conditions. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. Recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. The purpose of this TriMark Publications report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. It examines the use of stem cells in developing new therapies for disease.

Table of Contents

1. Overview

  • 1.1. Statement of the Report
  • 1.2. Scope of This Report
  • 1.3. Methodology
  • 1.4. Executive Summary

2. Biology of Stem Cells

  • 2.1. Scope of This Chapter
    • 2.1.1. Stem Cells
    • 2.1.2. Pluripotent Embryonic Stem Cells
    • 2.1.3. Induced Pluripotent Stem Cells (iPSC)
  • 2.2. Basic Properties of Stem Cells
    • 2.2.1. Capability of Self-Renewal
    • 2.2.2. Unspecialized Nature
    • 2.2.3. Ability to Give Rise to Specialized Cells
  • 2.3. Types of Human Stem Cells
    • 2.3.1. Embryonic Stem Cells
      • 2.3.1.1. Embryonic Stem Cell Research
    • 2.3.2. Embryonic Germ Cells
    • 2.3.3. Fetal Stem Cells
  • 2.4. Umbilical Cord Stem Cells
  • 2.5. Adult Stem Cells
    • 2.5.1. Hematopoietic Stem Cells
    • 2.5.2. Mesenchymal Stem Cells
    • 2.5.3. Gut Stem Cells
    • 2.5.4. Liver Stem Cells
    • 2.5.5. Epidermal Stem Cells (Skin and Hair)
    • 2.5.6. Neural Stem Cells
    • 2.5.7. Pancreatic Stem Cells
    • 2.5.8. Eye Stem Cells
  • 2.6. Induced Pluripotent Stem Cells
    • 2.6.1. Increased CIRM Funding for Induced Pluripotent Cells
    • 2.6.2. First iPSC Clinical Trial

3. Stem Cells as an Enabling Technology in Drug Discovery

  • 3.1. Immortalized Cells and Primary Cells in Current HTS
    • 3.1.1. Stem Cells in HTS and Drug Discovery
    • 3.1.2. Embryonic Stem Cells in HTS and Drug Discovery
  • 3.2. Adult Stem Cells in HTS and Drug Discovery
  • 3.3. Induced Pluripotent Stem Cells (iPSCs) in HTS and Drug Discovery

4. Clinical Trials in Cell Therapy Sector: An Overview

  • 4.1. The Soon-to-Arrive 15 Cell and Stem Cell Therapies in Phase III Clinical Trials
    • 4.1.1. Prochymal Stem Cell Therapy Sponsored by Osiris
    • 4.1.2. Prochymal for Crohn's Disease and Gastrointestinal Injury from Radiation
    • 4.1.3. MPC Product Cell Therapy Sponsored by Mesoblast
    • 4.1.4. MypCell Stem Cell Therapy Sponsored by Bioheart
    • 4.1.5. Ixmyelocel-T Stem Cell Therapy Sponsored by Aastrom
    • 4.1.6. ELAD Cell Therapy Sponsored by Vital Therapies
    • 4.1.7. HP802 Cell Therapy Sponsored by Healthpoint Biotherapeutics (Smith & Nephew)
    • 4.1.8. StemX Stem Cell Therapy Sponsored by Gamida Cell and Teva Pharmaceutical
    • 4.1.9. LAVIV Fibroblast Cell Therapy Sponsored by GlaxoSmithKline
    • 4.1.10. GSK 2696273 Stem Cell Therapy Sponsored by GlaxoSmithKline
    • 4.1.11. Adult Autologous Stem Cell Therapy Sponsored by Baxter International
    • 4.1.12. NT-501 Cell Therapy Sponsored by Neurotech Pharmaceuticals
    • 4.1.13. Neocart Cell Therapy Sponsored by Histogenics
    • 4.1.14. Juvenile Chondrocyte Grafts Cell Therapy Sponsored by ISTO Technologies
    • 4.1.15. MACI Cell Therapy Sponsored by Genzyme
  • 4.2. Cell Therapy Clinical Trials by Geography
  • 4.3. Cell Therapy Clinical Trials by Top Ten Countries
  • 4.4. Cell Therapy Clinical Trials by Type of Sponsorship
  • 4.5. Cell Therapy Clinical Trials by Cell Type
  • 4.6. Cell Therapy Clinical Trials by Stem Cell Type
  • 4.7. Stem Cell Therapy Clinical Trials Involving Non-Stem Cells
  • 4.8. Cell Therapy Involving MSCs by Source
  • 4.9. Clinical Trials Involving Stem Cells by Donor Type
  • 4.10. Cell Therapy Clinical Trials by Indication
  • 4.11. Cell and Tissue Therapy Clinical Trials by Phase of Development
  • 4.12. Clinical Development in Europe
    • 4.12.1. U.K. Cell Therapy Clinical Trials
    • 4.12.2. Cell Types Involved in U.K. Clinical Trials
    • 4.12.3. U.K. Cell Therapy Clinical Trials by Indication

5. Funding for Stem Cell Research

  • 5.1. Scope of This Chapter
  • 5.2. The Intense Competitive Pressure for Funding
  • 5.3. Funding in Leading Countries
    • 5.3.1. NIH Stem Cell Research Funding
    • 5.3.2. California Institute for Regenerative Medicine (CIRM) and Stem Cell Research
      • 5.3.2.1. CIRM Therapies in the Pipeline
      • 5.3.2.2. CIRM Stem Cell Therapy Research in Progress
      • 5.3.2.3. CIRM Projects in the Pipeline
      • 5.3.2.4. CIRM's Funding Intent
      • 5.3.2.5. Human Stem Cell Use
      • 5.3.2.6. CIRM Funded Research Categories
    • 5.3.3. Stem Cell Research Funding in the State of Connecticut
    • 5.3.4. Maryland Stem Cell Research Funds

6. Stem Cell Activity in Selected Countries

  • 6.1. U.S.
    • 6.1.1. Innovative Stem Cell Companies in the U.S.
      • 6.1.1.1. StemCells, Inc.
      • 6.1.1.2. Aastrom Biosciences
    • 6.1.2. Key Institutions in the U.S.
      • 6.1.2.1. California Institute for Regenerative Medicine
      • 6.1.2.2. The New York Stem Cell Foundation
      • 6.1.2.3. NIH Center for Regenerative Medicine
  • 6.2. Canada
    • 6.2.1. Innovative Stem Cell Companies in Canada
      • 6.2.1.1. Northern Therapeutics
      • 6.2.1.2. Octane Biotech
    • 6.2.2. Key Institutions in Canada
      • 6.2.2.1. Institute of Biomaterials & Biomedical Engineering, University of Toronto
      • 6.2.2.2. Terry Fox Research Institute
      • 6.2.2.3. Institute for Research in Immunology and Cancer, University of Montreal
  • 6.3. U.K.
    • 6.3.1. Innovative Companies in the U.K.
      • 6.3.1.1. Intercytex
      • 6.3.1.2. Azellon Cell Therapeutics
      • 6.3.1.3. Cell Medica
    • 6.3.2. Key Institutions in the U.K.
      • 6.3.2.1. Loughborough University
      • 6.3.2.2. U.K. Stem Cell Foundation
      • 6.3.2.3. University College, London
  • 6.4. Sweden
    • 6.4.1. Innovative Companies in Sweden
      • 6.4.1.1. Vitrolife
      • 6.4.1.2. Cellartis
      • 6.4.1.3. Biolamina
    • 6.4.2. Key Institutions
      • 6.4.2.1. Karolinska Institutet
      • 6.4.2.2. The University of Lund
  • 6.5. Brazil
    • 6.5.1. Innovative Company
      • 6.5.1.1. Excellion and CellPraxys
    • 6.5.2. Key Institutions
      • 6.5.2.1. Universidade de Sao Paulo
      • 6.5.2.2. Fiocruz and Hospital Sao Rafael
      • 6.5.2.3. Universidade Federal do Rio de Janeiro
      • 6.5.2.4. Pontificia Universidade Catolica do Parana

7. Commercial Cell Therapy Products

  • 7.1. Dermagraft
    • 7.1.1. Diabetic Foot Ulcer
  • 7.2. AlloStem
  • 7.3. MySkin
  • 7.4. CryoSkin
  • 7.5. PureGen
  • 7.6. BioDfactor
  • 7.7. CaReS
  • 7.8. ReCell
  • 7.9. Prokera
  • 7.10. AmnioGraft
  • 7.11. BioSeed-C
  • 7.12. Chondrotissue
  • 7.13. Celution System
  • 7.14. Provenge
  • 7.15. Epidex
  • 7.16. Hyalograft C
  • 7.17. LAVIV
  • 7.18. Epicel
  • 7.19. Carticel
    • 7.19.1. Carticel Implantation Procedure
  • 7.20. MACI Implant
  • 7.21. J-TEC Epidermis
  • 7.22. J-TEC Cartilage
  • 7.23. J-TEC Corneal Epithelium
  • 7.24. DIABECELL
  • 7.25. NuCel
  • 7.26. Osteocel Plus
  • 7.27. Apligraf
  • 7.28. GINTUIT
  • 7.29. Trinity Evolution
  • 7.30. ChondroCelect from TiCenix
  • 7.31. Grafix from Osiris
  • 7.32. DeNovo NT from Zimmer
  • 7.33. Hearticellgram-AMI
  • 7.34. Cartistem
  • 7.35. Cupistem
  • 7.36. CureXcell
  • 7.37. Prochymal
  • 7.38. Kaloderm
  • 7.39. Holoderm
  • 7.40. Neoderm

8. Regenerative Medicine Industry: An Overview

  • 8.1. The Major Divisions of Regenerative Medicine Industry
  • 8.2. The Three Major Sub-Sectors of Regenerative Medicine
  • 8.3. Cell and Tissue-Based Companies by Location
  • 8.4. Cell and Tissue-Based Clinical Trials by Location
  • 8.5. Cell and Tissue Therapies Being Sold or Tested
  • 8.6. Breakdown of Therapeutics Companies
  • 8.7. Gene Therapy Clinical Trials
    • 8.7.1. Distribution of Gene Therapy Clinical Trials by Country
    • 8.7.2. Indications Addressed by Gene Therapy Clinical Trials
    • 8.7.3. Vectors Used in Gene Therapy Clinical Trials
    • 8.7.4. Gene Types Transferred in Gene Therapy
    • 8.7.5. Number of Gene Therapy Clinical Trials Approved Worldwide

9. Cell Therapy Industry: An Overview

  • 9.1. Cell Based Therapies
    • 9.1.1. Cells as Immunotherapies
    • 9.1.2. Tissue Engineering
    • 9.1.3. Small Molecules and Biologics
    • 9.1.4. Stem Cells for Drug Discovery and Toxicity Testing
  • 9.2. Cell and Tissue Banking
  • 9.3. Industry Parameters for Tissue Engineering and Stem Cell Companies
    • 9.3.1. Commercial Products and Services in Tissue Engineering and Stem Cell Sector
    • 9.3.2. Breakdown of TE and Stem Cell Industry Spending by Segment
    • 9.3.3. Spending in the TE and Stem Cell Sector by Developmental Stage
    • 9.3.4. Number of Companies at Each Stage of Development
    • 9.3.5. Geographical Distribution of Spending for TE and Stem Industry
  • 9.4. Stem Cell Use in the U.S.
    • 9.4.1. Autologous Stem Cell Use in the U.S.
    • 9.4.2. Limbal Stem Cells
    • 9.4.3. Bone Marrow Stem Cells
    • 9.4.4. Adipose Tissue Stem Cells
    • 9.4.5. Allograft Stem Cell Use in the U.S.
  • 9.5. Cell Therapy and Regenerative Medicine Companies in Europe
    • 9.5.1. European Cell Therapy Product Approach
    • 9.5.2. Autologous vs. Allogeneic Firms in Europe
    • 9.5.3. Cell Therapies in Europe by Country
    • 9.5.4. European Stem Cell Platforms by Cell Source
    • 9.5.5. Stem Cell Therapy by Type in Europe

10. Stem Cell Therapy Industry: Market Analysis

  • 10.1. Economic Benefits of Cell Therapies and Regenerative Medicines
  • 10.2. Cell Therapy Industry and Capital Formation
  • 10.3. Cell Therapy Market Size and Value
  • 10.4. Structure of CTI
  • 10.5. CTI's Complementarities to Pharma, Biotech and Medical Device Industry
  • 10.6. Exploration to Exploitation of Cell Therapy
  • 10.7. Market Capitalization of Stem Cell Companies
  • 10.8. Global Market for Stem Cells
    • 10.8.1. U.S. Market for Stem Cells
    • 10.8.2. Stem Cell Market in Europe
  • 10.9. Cord Blood Banking
    • 10.9.1. Public Cord Blood Banks
      • 10.9.1.1. Collection Process
      • 10.9.1.2. Acceptance Criteria
      • 10.9.1.3. Processing
      • 10.9.1.4. Storage of Cord Blood
    • 10.9.2. Private Cord Blood Banks
      • 10.9.2.1. Public vs. Private Cord Blood Banking
    • 10.9.3. Dual Private-Public Banking of Cord Blood
    • 10.9.4. Worldwide Growth of Both Public and Private Cord Blood Banks
  • 10.10. Cell Therapy Market in Ophthalmology
    • 10.10.1. Cell Therapy Clinical Trials in Ophthalmology
  • 10.11. Cell Therapy in Cancer
  • 10.12. Global Market for CT and TE products for Cardiology and Vascular Diseases
  • 10.13. Market for CT and RM products in Neurology
  • 10.14. Global Market for CT and TE Products for Orthopedics, Musculoskeletal and Spine Disorders
  • 10.15. Global Market for CT and TE Products for Skin/Integument
  • 10.16. Cell Therapy in Dentistry
  • 10.17. Market for Cell Culture

11. Toxicity Testing

  • 11.1. Toxicity Tests
  • 11.2. History of Animal Use in Toxicity Testing
  • 11.3. Reasons for Deviating from Animal Tests
  • 11.4. Alternative Methods

12. Noteworthy Events in Cell Therapy Sector

  • 12.1. Clinical Milestones in Cell Therapy Sector, 2011-2012
  • 12.2. Recent Acquisitions and Partnerships in Cell Therapy Sector
  • 12.3. Noteworthy Financings in Cell Therapy Sector, 2010-2012
  • 12.4. Limited Pharma Engagement in Cell Therapy Sector, 2007-2012

13. Markers Used in Stem Cell Studies

14. Company Profiles

  • 14.1. Aastrom Biosciences
    • 14.1.1. Aastrom's Ixmyelocel-T
    • 14.1.2. Aastrom's Manufacturing Process
    • 14.1.3. Aastrom's Clinical Development Programs
    • 14.1.4. Aastrom's Patents and Proprietary Rights
  • 14.2. Advanced Cell Technology, Inc.
    • 14.2.1. ACT's Cell Therapy Research Programs
      • 14.2.1.1. ACT's Ophthalmology Programs
      • 14.2.1.2. Treating Macular Degeneration
      • 14.2.1.3. Photoreceptor Progenitor Program
      • 14.2.1.4. Retinal Ganglion Cell Progenitor Program
      • 14.2.1.5. Corneal Endothelial Program
      • 14.2.1.6. Neuroprotective Biologics
      • 14.2.1.7. Autoimmune/Inflammation Programs
      • 14.2.1.8. Platelet Program
      • 14.2.1.9. ACT's Intellectual Property
  • 14.3. AlloSource, Inc.
    • 14.3.1. Allografts from AlloSource
    • 14.3.2. Osteobiologics
      • 14.3.2.1. Traditional Grafts
      • 14.3.2.2. Spinal Grafts
      • 14.3.2.3. Sports Medicine Grafts
      • 14.3.2.4. Large Grafts
      • 14.3.2.5. Specialty Grafts
    • 14.3.3. Skin Allografts
  • 14.4. Asterand plc
    • 14.4.1. Asterand's Human Tissue and Biofluid Repository
    • 14.4.2. Frozen and Fixed Tissues
    • 14.4.3. RNA and DNA
    • 14.4.4. Biofluids
      • 14.4.4.1. Blood/Serum/Plasma
      • 14.4.4.2. Synovial Fluid
    • 14.4.5. Cell Lines
      • 14.4.5.1. Human Breast Cancer Cell Lines
      • 14.4.5.2. Prostrate Cell Lines
    • 14.4.6. Tissue Microarrays
      • 14.4.6.1. Human Primary Cells
  • 14.5. Athersy's, Inc.
    • 14.5.1. Athersys' Product Candidates
    • 14.5.2. Athersys' Pipeline
    • 14.5.3. MultiStem Programs
  • 14.6. BioE, Inc.
    • 14.6.1. Cell Technologies
      • 14.6.1.1. Application of BioE's MLPC
      • 14.6.1.2. Regenerative Medicine Applications
      • 14.6.1.3. Cord Blood Processing Applications
    • 14.6.2. Other Products
      • 14.6.2.1. PrepaCyte-WBC
      • 14.6.2.2. ActiCyte TC Media Kit
      • 14.6.2.3. VitaLyse Reagent System
  • 14.7. Bioheart, Inc.
    • 14.7.1. MyoCell
    • 14.7.2. MyoCell SDF-1
    • 14.7.3. MyoCath
    • 14.7.4. LipiCell
  • 14.8. BioMimetic Therapeutics, Inc.
    • 14.8.1. Augment Bone Graft
    • 14.8.2. Augment Injectable Bone Graft
    • 14.8.3. Augment Chronic Tendinopathy
    • 14.8.4. Augment Rotator Cuff Graft
  • 14.9. BioSafe Group SA
    • 14.9.1. Sepax 2
    • 14.9.2. Coolmix
    • 14.9.3. SepaxNet 2
  • 14.10. BioTime, Inc.
    • 14.10.1. PureStem Embryonic Progenitor Cells
      • 14.10.1.1. Ectoderm Progenitors
      • 14.10.1.2. Neural Crest Progenitors
      • 14.10.1.3. Mesoderm Progenitors
    • 14.10.2. PureStem Packages
    • 14.10.3. Recombinant Proteins
  • 14.11. Brainstorm Cell Therapeutics, Inc.
    • 14.11.1. Stem Cell Therapy
    • 14.11.2. NurOwn
  • 14.12. Cardio3 BioSciences
    • 14.12.1. Product Pipeline
      • 14.12.1.1. C3BS-CQR-1 (C-Cure)
      • 14.12.1.2. Protein (C3BS-GQR-1)
      • 14.12.1.3. C-CATHez
  • 14.13. Cellartis
    • 14.13.1. iPS Engineering Hub
    • 14.13.2. Cardiomyocyte Clusters
    • 14.13.3. Hepatocytes
    • 14.13.4. Stem Cell Culture Systems-DEF-CS
    • 14.13.5. Hepatocyte-Like Cells-hES-HEP
  • 14.14. Cellerant Therapeutics, Inc.
    • 14.14.1. Cellerant Pipeline
      • 14.14.1.1. CLT-008: Myeloid Progenitor Cells to Treat Neutropenia
      • 14.14.1.2. CLT-008 to Fight Acute Radiation Syndrome
      • 14.14.1.3. Cancer Stem Cell Antibodies
  • 14.15. CellSeed, Inc.
    • 14.15.1. Epithelial Cell Sheet for Corneal Regeneration
    • 14.15.2. Regenerated Cardiac Patch
    • 14.15.3. Epithelial Cell Sheet for Esophageal Regeneration
    • 14.15.3.1. Product Concept
    • 14.15.4. Cell Sheet for Periodontal Regeneration
    • 14.15.5. Regenerated Cartilage Sheet
  • 14.16. Cellular Dynamics International, Inc. (CDI)
    • 14.16.1. iCell Cardiomyocytes
    • 14.16.2. iCell Endothelial Cells
    • 14.16.3. iCell Hepatocytes
    • 14.16.4. iCell Neurons
    • 14.16.5. MyCell Products
  • 14.17. Cytori Therapeutics, Inc.
    • 14.17.1. Development Pipeline
    • 14.17.2. PureGraft 850
    • 14.17.3. PureGraft 250
    • 14.17.4. LipoBank
    • 14.17.5. Celbrush
  • 14.18. CryoLife, Inc.
    • 14.18.1. SynerGraft Technologies
    • 14.18.2. Cardiac Tissues
    • 14.18.3. Vascular Tissues
    • 14.18.4. HeRO Graft
    • 14.18.5. BioGlue
    • 14.18.6. BioFoam Surgical Matrix
  • 14.19. Forticell Bioscience, Inc.
    • 14.19.1. OrCel
  • 14.20. Gamida Cell
    • 14.20.1. StemEx
    • 14.20.2. NiCord
    • 14.20.3. CordBridge
    • 14.20.4. NK Cell Product
  • 14.21. Geron Corporation
    • 14.21.1. Hematologic Malignancies
    • 14.21.2. Imetelstat
  • 14.22. Humacyte, Inc.
    • 14.22.1. Investigational Biologic Grafts
  • 14.23. Intercytex Ltd.
    • 14.23.1. VAVELTA
  • 14.24. Integra LifeSciences Holdings Corporation
    • 14.24.1. DuraGen
    • 14.24.2. Integra Dermal Regeneration Template
    • 14.24.3. Integra Bilayer Wound Matrix
  • 14.25. International Stem Cell Corporation (ISCO)
    • 14.25.1. ISCO's Therapeutic Programs
    • 14.25.2. Parthenogenesis
  • 14.26. Japan Tissue Engineering Co., Ltd.
    • 14.26.1. Cultured Epidermis
    • 14.26.2. Cultured Cartilage
    • 14.26.3. Cultured Corneal Epithelium
  • 14.27. Medistem, Inc.
    • 14.27.1. Intellectual Property
      • 14.27.1.1. Method for Expansion of Stem Cells
      • 14.27.1.2. Placentally-Derived Stem Cells for the Treatment of Cancer
      • 14.27.1.3. Transcatheter Tumor Immunoembolization
      • 14.27.1.4. Stem Cell Therapy for Cardiac Valvular Dysfunction
      • 14.27.1.5. Allogeneic Stem Cell Transplants in Non-Conditioned Recipients
      • 14.27.1.6. Stem Cell Mediated Treg Activation for Therapeutic Immune Modulation
      • 14.27.1.7. Compositions and Methods of Stem Cell Therapy for Autism
      • 14.27.1.8. Stem Cell Therapy for Weight Loss
      • 14.27.1.9. Menstrual Blood Cellular Populations, Isolation and Use Thereof
      • 14.27.1.10. Endometrial Derived Reparative/Regenerative Cells
      • 14.27.1.11. Stem Cell Therapy for Autism
    • 14.27.2. Product Pipeline
      • 14.27.2.1. Endometrial Regenerative Cell Platform
      • 14.27.2.2. Angiostem Platform
      • 14.27.2.3. Tolerostem Cell Platform
  • 14.28. Mesoblast Ltd.
    • 14.28.1. Mesoblast's Products
      • 14.28.1.1. Rheumatoid Arthritis
      • 14.28.1.2. Type 2 Diabetes
      • 14.28.1.3. Intervertebral Disc Repair
      • 14.28.1.4. Spinal Fusion
      • 14.28.1.5. Congestive Heart Failure
      • 14.28.1.6. Heart Attack
  • 14.29. Millipore Corporation
  • 14.30. NeoStem, Inc.
    • 14.30.1. Therapeutic Targets
      • 14.30.1.1. Amrocyte
      • 14.30.1.2. Athelos
      • 14.30.1.3. VSEL Technology
  • 14.31. Neuralstem, Inc.
    • 14.31.1. NeuralStem Cell Therapy
  • 14.32. Opexa Therapeutics, Inc.
    • 14.32.1. Tcelna (Imilecleucel-T)
      • 14.32.1.1. Fast Track Regulatory Approval
  • 14.33. Organogenesis, Inc.
    • 14.33.1. Apligraf
    • 14.33.2. GINTUIT
  • 14.34. Osiris Therapeutics, Inc.
    • 14.34.1. Prochymal
    • 14.34.2. Chondrogen
  • 14.35. Regenocyte
    • 14.35.1. Adult Stem Cell Therapy
  • 14.36. ReNeuron Group plc
    • 14.36.1. ReN001 for Stroke
  • 14.37. Saneron CCEL Therapeutics, Inc.
    • 14.37.1. U-CORD-CELL Program
    • 14.37.2. SERT-CELL Program
  • 14.38. StemCells, Inc.
    • 14.38.1. Tools and Technologies
    • 14.38.2. Cell Lines
  • 14.39. StemCell Technologies, Inc.
    • 14.39.1. Products from Stem Cell Technologies
  • 14.40. Stem Cell Innovations, Inc.
    • 14.40.1. CNS Program
    • 14.40.2. SC Proven Products
      • 14.40.2.1. Cell Lines
      • 14.40.2.2. Cell Culture Products
      • 14.40.2.3. Antibody Detection Reagents
      • 14.40.2.4. Purified Whole Stem Cell Lysates
  • 14.41. Tengion, Inc.
    • 14.41.1. Tengion's Scientific Platform
    • 14.41.2. Tengion's Pipeline
  • 14.42. Terumo BCT
    • 14.42.1. Trima Accel Automated Blood Collection System
    • 14.42.2. COBE Spectra Apheresis System
    • 14.42.3. Elutra Cell Separation System
    • 14.42.4. Atreus Whole Blood Processing System
    • 14.42.5. Quantum Cell Expansion System
    • 14.42.6. Spectra Optia Apheresis System
    • 14.42.7. COBE 2991 Cell Processor
    • 14.42.8. Mirasol Pathogen Reduction Technology (PRT) System
    • 14.42.9. OrbiSac System
  • 14.43. ViaCyte, Inc.
    • 14.43.1. VC-01
  • 14.44. VistaGen Therapeutics, Inc.
    • 14.44.1. VistaGen's Technology
    • 14.44.2. CardioSafe 3D
    • 14.44.3. LiverSafe 3D
    • 14.44.4. AV 101
  • 14.45. ZenBio, Inc.
    • 14.45.1. Subcutaneous Preadipocytes and Adipocytes
    • 14.45.2. Visceral Preadipocytes and Adipocytes
    • 14.45.3. Hepatic Cells
    • 14.45.4. Skeletal Myoblasts
    • 14.45.5. Adult Stem Cells
    • 14.45.6. Human Dermal Fibroblasts
    • 14.45.7. Human Keratinocytes
    • 14.45.8. Human Mesothelial Cells
    • 14.45.9. Peripheral Blood Mononuclear Cells
    • 14.45.10. Human Mobilized Peripheral Blood CD34+ Progenitor Cells
    • 14.45.11. Human Umbilical Cord Blood Progenitor Cells
    • 14.45.12. Human Umbilical Vein Endothelial Cells (HUVEC)
    • 14.45.13. Human Mammary Luminal and Basal Epithelial Cells
    • 14.45.14. Human Melanocytes
    • 14.45.15. Human Sebocytes
    • 14.45.16. 3T3-L1
    • 14.45.17. Renal Proximal Convoluted Tubule Epithelial Cells
    • 14.45.18. ZenBio's Cell Culture Media

INDEX OF APPENDIXES:

  • Appendix 1: Strategic Roadmap to Cell Therapy Industry
  • Appendix 1.1: Options for Commercial Manufacturing of Stem Cell Products
  • Appendix 1.2: Regulations for a Cell Therapy Industry
  • Appendix 1.3: In-House Manufacturing of Cell Therapy Products
  • Appendix 1.4: Contract Manufacturing
  • Appendix 1.5: Effective Clinical Delivery Plan for Cell Therapies
  • Appendix 1.6: Business Models in Cell Therapy Sector
  • Appendix 1.6.1: Current Models for Autologous Cell Therapies
  • Appendix 1.6.2: Current Models for Allogeneic Cell Therapies
  • Appendix 1.7: Value Chain Considerations and Developmental Path
  • Appendix 1.8: Stem Cells: From the Laboratory to the Market
  • Appendix 1.9: Value Analysis
  • Appendix 1.10: Clinical Study Development
  • Appendix 1.11: Product Commercialization
  • Appendix 1.12: Importance of Specialty Society Support
  • Appendix 1.13: Payor Coverage
  • Appendix 2: Stem Cells: Research Spotlight, 2012
  • Appendix 2.1: Bioengineered Vein from Patient's Own Stem Cells
  • Appendix 2.2: Stem Cell Therapies to Repair Damaged Retina
  • Appendix 2.3: Bone Marrow Stem Cells in Heart Disease
  • Appendix 2.4: A Possible Cure for Deafness
  • Appendix 2.5: Clinical Trials of Stem Cell Therapies for CNS Disorders
  • Appendix 2.6: Key Developments in Stem Cell Therapy in Cardiology
  • Appendix 2.6.1: Recent Developments in Acute MI
  • Appendix 2.6.2: Chronic Ischemic Cardiomyopathy and Heart Failure
  • Appendix 2.7: Stem Cells and Neurodegenerative Diseases
  • Appendix 2.7.1: Modeling Diseases with iPS Cells
  • Appendix 2.7.2: Modeling Disease with Direct Neuronal Conversion
  • Appendix 2.7.3: Stem Cell Transplants for Neuronal Diseases
  • Appendix 2.8: Ophthalmologic Stem Cell Transplantation Therapies
  • Appendix 2.8.1: Stem Cell Types for Eye Disease Clinical Trials
  • Appendix 2.8.1.1: Pluripotent Stem Cells
  • Appendix 2.8.2: RPE and Photoreceptor Diseases
  • Appendix 2.8.3: Pluripotent Stem Cells for Retinal and RPE Degeneration
  • Appendix 2.8.4: Patch of hESC-Derived RPE Monolayer
  • Appendix 2.8.5: Patient-Derived RPE
  • Appendix 2.8.6: NSCs for AMD
  • Appendix 2.8.7: UCSCs for RP and AMD
  • Appendix 2.8.8: Bone Marrow Stem Cells for Photoreceptor Diseases
  • Appendix 2.8.9: Corneal Repair
  • Appendix 3: RM Clinical Milestones in the News, March 2012-March 2013
  • Appendix 4: Financial Overview of RM Sector
  • Appendix 4.1: Sector Activity
  • Appendix 4.2: Public Company Performance
  • Appendix 4.3: RM Financial News and Commercial Deals, 2012-2013
  • Appendix 5: Top 50 Stem Cell Influencers in Stem Cells Arena

INDEX OF FIGURES

  • Figure 2.1: Differentiation of Stem Cells into Adult Differentiated Cells
  • Figure 2.2: Pluripotent Embryonic Stem Cell
  • Figure 2.3: Induced Pluripotent Stem Cell (iPSC)
  • Figure 2.4: Differentiation of Stem Cells into Specialized Cells
  • Figure 2.5: Clinical Trials Using MSCs by Disease Type
  • Figure 2.6: Induction and Differentiation of iPSCs
  • Figure 3.1: Outline of Drug Discovery Process
  • Figure 3.2: The Development of Totipotent, Pluripotent and Multipotent Stem Cells
  • Figure 4.1: Number of Cell Therapy Clinical Trials (Total 226) by Geography, 2012
  • Figure 4.2: Number of Cell Therapy Clinical Trials by Top Ten Countries, 2012
  • Figure 4.3: Cell Therapy Clinical Trials by Type of Sponsorship, 2012
  • Figure 4.4: Cell Therapy Clinical Trials by Cell Type, 2012
  • Figure 4.5: Cell Therapy Clinical Trials by Stem Cell Type, 2012
  • Figure 4.6: Stem Cell Therapy Clinical Trials Involving Non-Stem Cells, 2012
  • Figure 4.7: Cell Therapy Involving MSCs by Source, 2012
  • Figure 4.8: Clinical Trials Involving Stem Cells by Donor Type, 2012
  • Figure 4.9: Cell Therapy Clinical Trials by Indication, 2012
  • Figure 4.10: Global Cell and Tissue Therapy Clinical Trials by Phase, 2012
  • Figure 4.11: Cell Therapy Products Currently in Late Stage Trials (Phase II/III, III, Pivotal), 2012
  • Figure 4.12: Currently in Early-to-Mid Stage Trials (Phase I, I/II, II), 2012
  • Figure 4.13: Clinical Trials for Commercial Cell Therapy Products, 2012
  • Figure 4.14: Stem Cell Therapy Clinical Development in Europe
  • Figure 4.15: Somatic Cell Therapy Clinical Development in Europe
  • Figure 4.16: Cell Types in U.K. Clinical Trials, 2013
  • Figure 4.17: U.K. Cell Therapy Clinical Trials by Indication
  • Figure 5.1: Increase in Worldwide Funding for Cell Therapy Research, 2008-2018
  • Figure 5.2: CIRM Funds for Stem Cell Research Committed, 2007-2012
  • Figure 5.3: CIRM Therapy Investment by Stem Cell Type, 2012
  • Figure 5.4: CIRM's Funding Intent, 2012
  • Figure 5.5: Stem Cell Derivation by Award Number
  • Figure 5.6: CIRM Funded Disease Categories by Award Number, 2012
  • Figure 7.1: Worldwide Sales of Carticel, 2010-2012
  • Figure 8.1: Cell Therapy: The Largest Component of Regenerative Medicine Industry
  • Figure 8.2: The Three Broad Divisions of Regenerative Medicine
  • Figure 8.3: The Three Major Sub-Sectors of Regenerative Medicines
  • Figure 8.4: Cell and Tissue-Based Companies by Location, 2012
  • Figure 8.5: Cell and Tissue-Based Clinical Trials by Location, 2012
  • Figure 8.6: Cell and Tissue Therapies Being Sold or Tested, 2012
  • Figure 8.7: Breakdown of Therapeutics Companies
  • Figure 8.8: Number of Gene Therapy Clinical Trials, 2013
  • Figure 8.9: Geographical Distribution of Gene Therapy Trials by Country, 2013
  • Figure 8.10: Indications Addressed by Gene Therapy Clinical Trials, 2013
  • Figure 8.11: Vectors Used in Gene Therapy Clinical Trials, 2013
  • Figure 8.12: Gene Types Transferred in Gene Therapy, 2013
  • Figure 8.13: Number of Gene Therapy Clinical Trials Approved Worldwide, 1989-2012
  • Figure 9.1: Cell Therapy Industry Sectors
  • Figure 9.2: Tissue Engineering Companies Worldwide, 2013
  • Figure 9.3: Percent of Public vs. Private TE Companies Worldwide
  • Figure 9.4: Cell and Tissue Banks Breakdown
  • Figure 9.5: AAB and FACT Accredited Cord Blood Banks by Geography, 2013
  • Figure 9.6: Breakout of Spending for Preclinical Studies by Product Platform
  • Figure 9.7: Breakout of Spending for TE and Stem Cell Clinical Trials
  • Figure 9.8: Breakout of Spending for Commercial TE and Stem Cell Products
  • Figure 9.9: Breakout of Spending for TE and Stem Cell Services
  • Figure 9.10: Spending by TE and Stem Cell Therapeutics Developmental Stages by Total Spending
  • Figure 9.11: Number of TE and Stem Cell Companies by Stage of Development
  • Figure 9.12: Geographical Distribution of Spending for TE and Stem Industry
  • Figure 9.13: Total Number of Cell Therapy and Regenerative Medicine Companies by Continent
  • Figure 9.14: Number of Cell Therapy and Regenerative Medicine SMEs in Selected European Countries
  • Figure 9.15: European Stem Cell SMEs by Type and Tissue Source
  • Figure 9.16: European Somatic SMEs by Type and Tissue Source
  • Figure 9.17: Concentration of European Cell Therapy Firms, 2012
  • Figure 9.18: European Stem Cell Platforms by Cell Source
  • Figure 9.19: Stem Cell Therapy by Type in Europe
  • Figure 9.20: Somatic Cell Therapy by Type in Europe
  • Figure 10.1: Indicator of Frequency of General Usage of the Terms “Tissue Engineering,” “Regenerative Medicine” and “Cell Therapy”, 2003-2011
  • Figure 10.2: The Cost Impact of Aging Population in the U.S., 2010 and 2030
  • Figure 10.3: Cell Therapy Industry (CTI) Market, 2008-2014
  • Figure 10.4: Global Market for Stem Cells, 2012-2019
  • Figure 10.5: U.S. Stem Cell Market, 2012-2019
  • Figure 10.6: European Stem cell Market, 2012-2019
  • Figure 10.7: Global Market for Stem Cell Banking, 2012-2019
  • Figure 10.8: Worldwide Growth of (CAGR = 6.5%) Public Cord Blood Banks, 2005-2012
  • Figure 10.9: Worldwide Growth (CAGR = 15.2%) of Private Cord Blood Banks, 2005-2012
  • Figure 10.10: Worldwide Growth (CAGR = 20.8%) of Public/Private Cord Blood Banks, 2005-2012
  • Figure 10.11: Worldwide Growth (CAGR = 11.0%) of Both Public and Private Cord Blood Banks, 2005-2012
  • Figure 10.12: Global Market for CT and TE in Ophthalmology, 2012-2019
  • Figure 10.13: Global Market for CT and TE Products in Cancer, 2012-2019
  • Figure 10.14: Global Market for CT and TE Products for Cardiology and Vascular Diseases, 2012-2019
  • Figure 10.15: Global Market for CT and TE Products for Neurological Diseases, 2012-2019
  • Figure 10.16: Global Market for CT and TE Products for Orthopedics, Musculoskeletal and Spine Disorders, 2012-2019
  • Figure 10.17: Global Market for CT and TE Products for Skin/Integument, 2012-2019
  • Figure 10.18: Global Market for CT and TE Products for Dental/Oral Applications, 2012-2019
  • Figure 10.19: Global Market for Reagents, Media and Sera, 2012-2019
  • Figure 10.20: Global Market for Cell Culture Reagents, 2012-2019
  • Figure 10.21: Global Market for Cell Culture Media, 2012-2019
  • Figure 10.22: Global Market for Cell Culture Sera, 2012-2019
  • Figure 13.1: Markers Used to characterize hESCs
  • Figure 13.2: Markers Used to Characterize MSCs
  • Figure 13.3: Markers Used in Neural Stem Cell Studies
  • Figure A1.1: Value Chain of Mesenchymal Stem Cell Therapeutics
  • Figure A1.2: Use of Coverage and Reimbursement Knowledge in the Product Life Cycle
  • Figure A2.1: Eye Tissues Being Targeted for Stem Cell Replacement
  • Figure A2.2: Human Stem Cell Sources Explored for Eye Tissue Replacement
  • Figure A4.1: Public vs. Private Regenerative Medicine Companies, 2013
  • Figure A4.2: RM Sector Investment Breakdown, 2013
  • Figure A4.3: Comparison of S&P to Underweighted Regenerative Medicine Index, March 2012-March 2013
  • Figure A4.4: Comparison of NASDAQ to Underweighted Regenerative Medicine Index, March 2012-March 2013

INDEX OF TABLES

  • Table 3.1: Stem Cells Isolated from Embryonic or Adult Sources
  • Table 4.1: U.K. Cell Therapy Clinical Trials, 2012 and 2013
  • Table 5.1: NIH Stem Cell Research Funding, 2002-2012
  • Table 5.2: CIRM Stem Cell Research in Progress
  • Table 5.3: CIRM's Therapy Development Projects
  • Table 5.4: CIRM Funding for Huntington's Disease, 2013
  • Table 5.5: CIRM Funding Heart Diseases, 2013
  • Table 5.6: CIRM Grants Targeting HIV/AIDS
  • Table 5.7: Stem Cell Research Funding in the State of Connecticut, 2013
  • Table 7.1: Currently Available Cell Therapy Products
  • Table 9.1: Cell Therapies Available by Geography/Country, March 2013
  • Table 9.2: Key Industry Parameters: Tissue Engineering and Stem Cell Therapeutics, 2007 and 2011
  • Table 9.3: Sales of Commercial Tissue Engineering and Stem Cell Products, 2011
  • Table 9.4: Partial List of Firms Supporting Stem Cell Industry
  • Table 10.1: Industry-Sponsored Active Cell Therapy Clinical Trials, 2007 and 2012
  • Table 10.2: Market Capitalization of Stem Cell Companies, 2011 and 2012
  • Table 10.3: Stem Cell Therapy in Ophthalmology by Application as of April 2013
  • Table 11.1: Selected Suppliers of In Vitro Test Kits, 2013
  • Table 11.2: Selected Cell and Tissue Suppliers, 2013
  • Table 11.3: Selected Suppliers of Media and Cell Reagents, 2013
  • Table 11.4: Selected Cell Culture Equipment and other Product Suppliers, 2013
  • Table 11.5: Selected Suppliers of Software for Cell Culture, 2013
  • Table 14.1: Aastrom's Active Clinical Programs, 2012
  • Table 14.2: Number of U.S. Patents with Expiration Range
  • Table 14.3: ACT's Pipeline of Therapeutic Programs, 2012
  • Table 14.4: Patents Owned by ACT, 2012
  • Table 14.5: Development Status of Athersys' Key Programs
  • Table 14.6: Cardio3 Biosciences' Product Pipeline
  • Table 14.7: Cellerant's Pipeline
  • Table A1.1: Elements of a Cell Therapy Manufacturing Facility
  • Table A1.2: Cell Therapy CMO Qualification Audit: Points to Investigate
  • Table A1.3: Areas for Coverage and Reimbursement Competency and Planning
  • Table A2.1: Recently Published Stem Cell Therapy Clinical Trials for Ischemic Heart Disease
  • Table A4.1: Companies Included in the Underweighted Regenerative Medicine Index
Back to Top